CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Imaging of the lungsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Long-term Pulmonary Outcomes After Infection With Sars-CoV-2

The objective of this study is to assess the long-term outcomes after hospital admission with Covid-19 with respect to pulmonary function, physical capacity, imaging, quality of life and socioeconomic outcomes.

NCT04401163 Sars-CoV2 Covid19 Diagnostic Test: Imaging of the lungs
MeSH:Infection

Primary Outcomes

Description: Expert evaluation

Measure: Imaging of the lungs

Time: 3 months after discharge

Description: Expert evaluation

Measure: Imaging of the lungs

Time: 12 months after discharge

Description: Liter

Measure: Pulmonary function tests

Time: 3 months after discharge

Description: Liter

Measure: Pulmonary function tests

Time: 12 months after discharge

Description: Walking distance (meters) and change in oxygen saturation.

Measure: Six-minute walk test

Time: Performed 3 months after discharge

Description: Walking distance (meters) and change in oxygen saturation.

Measure: Six-minute walk test

Time: Performed 12 months after discharge

Secondary Outcomes

Description: 0-100 scale. The lower the score, the more disability.

Measure: Short Form-36 (SF-36) questionnaire

Time: 3 months after discharge

Description: 0-100 scale. The lower the score, the more disability.

Measure: Short Form-36 (SF-36) questionnaire

Time: 12 months after discharge

Description: 10-50 score. The higher the score, the more fatigue

Measure: Fatigue Assessment Score

Time: 3 months after discharge

Description: 10-50 score. The higher the score, the more fatigue

Measure: Fatigue Assessment Score

Time: 12 months after discharge

Description: 0-30. The lower the score, the more cognitive impairment

Measure: Cognitive sore (MOCA)

Time: 3 months after discharge

Description: 0-30. The lower the score, the more cognitive impairment

Measure: Cognitive sore (MOCA)

Time: 12 months after discharge

Description: 0-21. The higher the score, the more risk of anxiety or depression.

Measure: Hospital anxiety and Depression score (HADS)

Time: 3 months after discharge

Description: 0-21. The higher the score, the more risk of anxiety or depression.

Measure: Hospital anxiety and Depression score (HADS)

Time: 12 months after discharge

Description: Any pre-COVID-19 comorbidity and treatment with immmunosuppressants will be registered.

Measure: Comorbidities

Time: 12 months after discharge

Description: Change in outcomes between discharge and follow-up visits will be evaluated

Measure: Blood sample at routine follow up.

Time: 3 months after discharge

Description: Change in outcomes between discharge and follow-up visits will be evaluated

Measure: Blood sample at routine follow up.

Time: 12 months after discharge

Description: Knowledge regarding COVID19 is drastically evolving. Biobanking makes it possible to investigate blood samples in the future corresponding to ongoing evidence.

Measure: Biobanking of blood

Time: 3 months after discharge

Description: Knowledge regarding COVID19 is drastically evolving. Biobanking makes it possible to investigate blood samples in the future corresponding to ongoing evidence.

Measure: Biobanking of blood

Time: 12 months after discharge

No related HPO nodes (Using clinical trials)